Novartis Finishes Up $51.6B Alcon Purchase

Law360, New York (December 15, 2010, 1:49 PM EST) -- Swiss drug giant Novartis AG wrested full control of eye care company Alcon Inc. on Wednesday after almost a year of regulatory and shareholder battles in the $51.6 billion deal.

To complete the long-awaited takeover, Novartis will buy Alcon's remaining stock for $12.9 billion, or $168 per share. In January, Novartis paid about $38.7 billion for 77 percent of the company in a deal with Nestle SA.

"The full merger is the logical conclusion of our initial strategic investment in Alcon," Dr. Daniel Vasella, chairman and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.